1 minute read

Health Economics and Patient Value

HEALTH ECONOMICS AND PATIENT VALUE

MDIC’s Health Economics and Patient Value (HEPV) initiative, previously called Health Economics and Patient Access, was established in 2018. This initiative aims to create predictability and transparency of evidence requirements for coverage, speed patient access, and amplify the patient voice in the selection of treatment options. Building off successful projects in regulatory science, the MDIC Board identified an equally important need to create predictability within CMS and private payer evidentiary processes. HEPV is developing projects and focusing on tools to increase predictability of payer scientific and evidentiary requirements.

Advertisement

Health Economics and Patient Value: 2019 Accomplishments

Health Economics and Patient Value Member Survey

Following initial meetings to define the objectives of the HEPV initiative, understand reimbursement challenges, and gather priority areas for engagement, the HEPV steering committee initiated a survey to further define “pain points” with both CMS and private payer coverage processes. MDIC surveyed 34 medical device and diagnostic industry stakeholders on how their companies navigate the coverage process for innovative technologies with public and private payers.

Within the survey responses, MDIC found that the major reimbursement challenges for industry fell in the following categories:

Lack of transparency in private payer evidentiary requirements Lag between FDA approval and private payer coverage Lag between CMS coverage decision and coding and/or payment decisions Patient preference data included in regulatory decision-making is not considered for coverage

MDIC also identified the following key factors impacting patient access:

FDA approval or clearance Private payer coverage Local coverage National coverage

These responses will help inform the HEPV committee on where to best collaborate on process improvements and enhancements to coverage decisionmaking methodologies.

Health Economics and Patient Value Member Survey Reimbursement Challenges

Lack of transparency in private payer evidentiary requirements Lag between CMS coverage decision and coding and/or payment decisions

Lag between FDA approval and private payer coverage Patient preference data included in regulatory decision-making is not considered for coverage

This article is from: